Home LiteratureArticle Details
PMID: 24379816 Published · epublish English Journal Article Review

Dendritic cells in cancer immunotherapy clinical trials: are we making progress?

Frontiers in immunology ·Vol. 4 ·2013-12-13 ·Pages 454

Butterfield LH

Abstract

Dendritic cells (DC) have been tested in cancer immunotherapy clinical trials for two decades. Over this time, the methods of DC culture (or manufacture) have evolved, the approaches for antigen loading have broadened, the maturation signals have varied and different sites of administration have been tested. The post-vaccination immunologic questions asked have also varied between trials and over time. In this review, I will consider multiple aspects of DC-based vaccines tested in cancer patients, including the cell culture, antigen loading, maturation, and delivery, as well as what we have learned from testing immune responses in vaccinated patients who have benefited clinically, and those who have not measurably benefited.

Keywords
antigen loading antigen presentation cancer vaccines dendritic cells tumor immunology
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Butterfield Lisa H
Departments of Medicine, Surgery and Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh , Pittsburgh, PA , USA.
References (52)
52 references, click to expand
  1. T cell assays and MIATA: the essential minimum for maximum impact.
    Immunity. 2012 Jul 27;37(1):1-2 PMID: 22840835
  2. Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen.
    Oncoimmunology. 2012 May 1;1(3):263-270 PMID: 22737601
  3. Functional assessment of human dendritic cells labeled for in vivo (19)F magnetic resonance imaging cell tracking.
    Cytotherapy. 2010 Apr;12(2):238-50 PMID: 20053146
  4. Proliferating dendritic cell progenitors in human blood.
    J Exp Med. 1994 Jul 1;180(1):83-93 PMID: 8006603
  5. Fast generation of dendritic cells.
    Cell Immunol. 2009;260(1):56-62 PMID: 19818956
  6. Cancer classification using the Immunoscore: a worldwide task force.
    J Transl Med. 2012 Oct 03;10:205 PMID: 23034130
  7. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.
    Clin Cancer Res. 2009 Sep 1;15(17):5323-37 PMID: 19723653
  8. Immune selective pressure and HLA class I antigen defects in malignant lesions.
    Cancer Immunol Immunother. 2007 Feb;56(2):227-36 PMID: 16783578
  9. A prescription for human immunology.
    Immunity. 2008 Dec 19;29(6):835-8 PMID: 19100694
  10. Type I interferon response and innate immune sensing of cancer.
    Trends Immunol. 2013 Feb;34(2):67-73 PMID: 23122052
  11. The secret ally: immunostimulation by anticancer drugs.
    Nat Rev Drug Discov. 2012 Feb 03;11(3):215-33 PMID: 22301798
  12. Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates.
    Am J Transplant. 2013 Aug;13(8):1989-2005 PMID: 23758811
  13. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL.
    J Immunol. 2006 Mar 15;176(6):3402-9 PMID: 16517708
  14. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity.
    Cancer Res. 2004 Sep 1;64(17):5934-7 PMID: 15342370
  15. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
    Clin Cancer Res. 2006 Oct 1;12(19):5801-8 PMID: 17020987
  16. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution.
    J Exp Med. 1973 May 1;137(5):1142-62 PMID: 4573839
  17. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
    Nat Med. 1998 Mar;4(3):328-32 PMID: 9500607
  18. Development of a potency assay for human dendritic cells: IL-12p70 production.
    J Immunother. 2008 Jan;31(1):89-100 PMID: 18157016
  19. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters.
    Cancer Immunol Immunother. 2009 Jan;58(1):1-14 PMID: 18719915
  20. Cancer immunotherapy: moving beyond current vaccines.
    Nat Med. 2004 Sep;10(9):909-15 PMID: 15340416
  21. Cancer immunotherapy via dendritic cells.
    Nat Rev Cancer. 2012 Mar 22;12(4):265-77 PMID: 22437871
  22. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro.
    J Clin Invest. 1990 Mar;85(3):955-61 PMID: 2179270
  23. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.
    Cancer Prev Res (Phila). 2013 Jan;6(1):18-26 PMID: 23248097
  24. Biodistribution of radiolabelled human dendritic cells injected by various routes.
    Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):731-41 PMID: 15924229
  25. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy.
    Nat Biotechnol. 2005 Nov;23(11):1407-13 PMID: 16258544
  26. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state.
    Cancer Res. 2003 Jan 1;63(1):12-7 PMID: 12517769
  27. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
    Cancer Res. 2001 Sep 1;61(17):6451-8 PMID: 11522640
  28. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.
    Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):8078-82 PMID: 7644541
  29. Cancer immunology.
    N Engl J Med. 2008 Jun 19;358(25):2704-15 PMID: 18565863
  30. Dendritic-cell-based therapeutic cancer vaccines.
    Immunity. 2013 Jul 25;39(1):38-48 PMID: 23890062
  31. Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy.
    Melanoma Res. 2006 Apr;16(2):137-45 PMID: 16567969
  32. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients.
    Cancer Res. 2006 Jun 1;66(11):5910-8 PMID: 16740731
  33. Superior efficacy of tumor cell vaccines grown in physiologic oxygen.
    Clin Cancer Res. 2010 Oct 1;16(19):4800-8 PMID: 20858839
  34. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.
    Clin Cancer Res. 2013 Jul 1;19(13):3640-8 PMID: 23685836
  35. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients.
    Diabetes Care. 2011 Sep;34(9):2026-32 PMID: 21680720
  36. Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products.
    Vaccine. 2007 Sep 27;25 Suppl 2:B47-60 PMID: 17669561
  37. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
    Clin Cancer Res. 2013 Sep 1;19(17):4801-15 PMID: 23838316
  38. Trial watch: Dendritic cell-based interventions for cancer therapy.
    Oncoimmunology. 2012 Oct 1;1(7):1111-1134 PMID: 23170259
  39. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
    J Clin Oncol. 2011 Jan 20;29(3):330-6 PMID: 21149657
  40. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
    Ann Oncol. 2006 Oct;17(10):1592-7 PMID: 17005632
  41. Migration of human dendritic cells after injection in patients with metastatic malignancies.
    Cancer Res. 1999 Jan 1;59(1):56-8 PMID: 9892184
  42. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
    Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13824-9 PMID: 20631300
  43. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.
    Clin Cancer Res. 2003 Mar;9(3):998-1008 PMID: 12631598
  44. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.
    Clin Cancer Res. 2011 May 15;17(10):3064-76 PMID: 21558394
  45. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.
    Nature. 2005 Mar 3;434(7029):88-93 PMID: 15744305
  46. Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?
    Immunol Res. 2011 Aug;50(2-3):235-47 PMID: 21717071
  47. Dendritic cells and immunity against cancer.
    J Intern Med. 2011 Jan;269(1):64-73 PMID: 21158979
  48. Immune parameters affecting the efficacy of chemotherapeutic regimens.
    Nat Rev Clin Oncol. 2011 Mar;8(3):151-60 PMID: 21364688
  49. Identification of proliferating dendritic cell precursors in mouse blood.
    J Exp Med. 1992 May 1;175(5):1157-67 PMID: 1569392
  50. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.
    Nat Med. 1996 Jan;2(1):52-8 PMID: 8564842
  51. Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies.
    J Transl Med. 2010 Jan 15;8:4 PMID: 20078880
  52. Quality controls in cellular immunotherapies: rapid assessment of clinical grade dendritic cells by gene expression profiling.
    Mol Ther. 2013 Feb;21(2):476-84 PMID: 23147403
Article Info
Journal
Frontiers in immunology
Abbr.
Front Immunol
ISSN
1664-3224
DOI
10.3389/fimmu.2013.00454
Published
2013-12-13
Epub
2013-00-13
Pages
454
Language
English
Region
Switzerland
NLM ID
101560960
PMCID
PMC3861778
Grants
NCI NIH HHS · P30 CA047904 · United States
NCI NIH HHS · P50 CA121973 · United States
External Links
PubMed source DOI: 10.3389/fimmu.2013.00454 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2